| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | T2 BIOSYSTEMS INC | 2,269,578 | 36,835,000 | 16.43% | ||
| 2 | PULMATRIX INC | 3,607,996 | 34,637,000 | 15.45% | ||
| 3 | Life Technologies Corp | 1,827,992 | 33,854,000 | 15.10% | ||
| 4 | GENOCEA BIOSCIENCES INC | 1,968,606 | 27,029,000 | 12.05% | ||
| 5 | OCULAR THERAPEUTIX INC | 1,230,009 | 25,867,000 | 11.54% | ||
| 6 | TREVENA INC | 3,769,280 | 23,596,000 | 10.52% | ||
| 7 | FATE THERAPEUTICS INC COM | 2,473,186 | 16,002,000 | 7.14% | ||
| 8 | CERULEAN PHARMA INC | 3,287,529 | 15,123,000 | 6.74% | ||
| 9 | BIND THERAPEUTICS INC | 2,018,253 | 11,282,000 | 5.03% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0000950123-15-008468, filed 2015.08.11).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
